[1] Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. DOI:
10.1177/1060028018797110[2] Campbell RW, et al. Mexiletine. N Engl J Med. 1987,316(1):29-34. DOI:
10.1056/NEJM198701013160106[3] De Bellis M, et al. Combined modifications of mexiletine pharmacophores for new lead blockers of Na(v)1.4 channels. Biophys J. 2013,104(2):344-54. DOI:
10.1016/j.bpj.2012.11.3830[4] Nasilli G, et al. Mexiletine reverses oxaliplatin-induced neuropathic pain in rats. J Pharmacol Sci. 2010;112(4):473-6. DOI:
10.1254/jphs.10012sc[5] Egashira N, et al. Mexiletine reverses oxaliplatin-induced neuropathic pain in rats. J Pharmacol Sci. 2010,112(4):473-6. DOI:
10.1254/jphs.10012sc